natgillin/translations-raw huggingface dataset:
You can take Repaglinide Teva with metformin, another medicine for diabetes, if your doctor prescribes it. 
Repaglinid Teva možete uzimati u kombinaciji s metforminom, drugim lijekom protiv šećerne bolesti, ako ga liječnik propiše.
Repaglinide Teva is not recommended in patients with moderate liver disease. 
Repaglinid Teva se ne preporučuje u bolesnika koji imaju srednje tešku bolest jetre.
Repaglinide has been shown to lower the blood sugar, which helps to prevent complications from your diabetes. 
Repaglinid snižava razinu šećera u krvi i time pomaže u sprječavanju komplikacija šećerne bolesti.
In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage. 
U slučaju istodobne primjene s drugim djelatnim tvarima doziranje treba procijeniti na temelju navedenog u dijelovima 4.4 i 4.5. 4.3 Kontraindikacije
• Phenytoin, carbamazepine, phenobarbital (used to treat epilepsy). 
• fenitoin, karbamazepin, fenobarbital (koriste se za liječenje epilepsije)
• Sympathomimetics (used to treat asthma). 
• simpatomimetike (koriste se za liječenje astme)
Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). 
Učestalost je definirana kao: često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do
Repaglinide Teva is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose). 
Repaglinid Teva je lijek protiv šećerne bolesti za primjenu kroz usta, a sadrži repaglinid koji pomaže gušterači da stvori više inzulina te tako snizi razinu šećera (glukoze) u krvi.
• If you take too little Repaglinide Teva. 
• ako uzmete premalo lijeka Repaglinid Teva.
The following substances may reduce the hypoglycaemic effect of repaglinide: Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol, thyroid hormones and sympathomimetics. 
oralni kontraceptivi, rifampicin, barbiturati, karbamazepin, tiazidi, kortikosteroidi, danazol, hormoni štitnjače i simpatomimetici.
Repaglinide Teva can also be given with metformin, another medicine for diabetes. 
Repaglinid Teva se može primjenjivati i u kombinaciji s metforminom, drugim lijekom protiv šećerne bolesti.
• If you are allergic to repaglinide or any of the other ingredients in this medicine (listed in section 6). 
Nemojte uzimati Repaglinid Teva • ako ste alergični na repaglinid ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
One epidemiological study suggested an increased risk of acute coronary syndrome in repaglinide treated patients as compared to sulfonylurea treated patients (see sections 4.4 and 4.8). 
U jednom epidemiološkom ispitivanju primijećen je povećan rizik razvoja akutnog koronarnog sindroma u bolesnika liječenih repaglinidom u usporedbi s bolesnicima liječenih sulfonilurejom
The recommended starting dose is 0.5 mg. One to two weeks should elapse between titration steps (as determined by blood glucose response). 
Između svakog koraka titracije doze trebalo bi proći jedan do dva tjedna (na temelju mjerenja odgovora razine glukoze u krvi).
• If you take too much Repaglinide Teva. 
• ako uzmete previše lijeka Repaglinid Teva.
• Thiazides (diuretics or ‘water pills'). 
• tiazide (diuretici ili lijekovi za izmokravanje)
The blood glucose-lowering effect of oral hypoglycaemic medicinal products decreases in many patients over time. 
Kombinacija s lijekovima koji potiču izlučivanje inzulina Učinak oralnih antidijabetika na snižavanje razine glukoze u krvi u mnogih bolesnika se s vremenom smanjuje.
If patients are transferred from another oral hypoglycaemic medicinal product, the recommended starting dose is 1 mg. 
Ako su bolesnici prethodno bili liječeni drugim oralnim antidijabetikom, preporučena početna doza je
Marketing Authorisation Holder Teva B.V. 
ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Teva B.V.
Data from animal studies investigating effects on embryofetal and offspring development as well as excretion in milk is described in section 5.3. 
Podaci o učincima na embriofetalni razvoj i razvoj mladunčadi te izlučivanju u majčino mlijeko dobiveni u ispitivanjima na životinjama opisani su u dijelu 5.3. 4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima
• have few or no warning signs of hypos. 
• imate malo znakova hipoglikemije ili oni izostaju.
Seven days pre-treatment with rifampicin (600 mg), followed by co-administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition). 
Prethodna terapija rifampicinom (600 mg) tijekom 7 dana, a potom dodavanje repaglinida (pojedinačna doza od 4 mg) sedmoga je dana rezultirala 50% nižom AUC
Repaglinide Teva 2 mg tablets EU/1/09/530/011-015 
Repaglinid Teva 2 mg tablete EU/1/09/530/011-015
NAME OF THE MARKETING AUTHORISATION HOLDER Teva B.V. 
Nositelj odobrenja za stavljanje lijeka u promet Teva B.V.
Repaglinide Teva 1 mg tablets EU/1/09/530/006-010 
Repaglinid Teva 1 mg tablete EU/1/09/530/006-010
You should not take Repaglinide Teva if you are breast-feeding. 
Ne smijete uzimati Repaglinid Teva ako dojite.
Repaglinide Teva 0.5 mg tablets EU/1/09/530/001-005 
Repaglinid Teva 0,5 mg tablete EU/1/09/530/001-005
If you take more Repaglinide Teva than you should If you take too many tablets, your blood sugar may become too low, leading to a hypo. 
Ako uzmete previše tableta, može doći do prevelikog pada razine šećera u krvi, što vodi u hipoglikemiju.
Repaglinide Teva 0.5 mg tablets Each tablet contains 0.5 mg of repaglinide. 
Repaglinid Teva 0,5 mg tablete Svaka tableta sadrži 0,5 mg repaglinida.
• Thyroid products (used to treat low levels of thyroid hormones). 
• hormone štitnjače (koriste se za liječenje niske razine hormona štitnjače)
In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0-∞) 5.1-fold and continued administration (75 mg daily dose) increased repaglinide exposure (AUC0-∞) 3.9-fold. 
U ispitivanju interakcija u zdravih dobrovoljaca, istodobna primjena klopidogrela (udarna doza od 300 mg), inhibitora CYP2C8, povećala je izloženost repaglinidu (AUC0-∞) 5,1 puta, a nakon kontinuirane primjene (dnevna doza od 75 mg) povećala se izloženost repaglinidu (AUC0-∞) 3,9 puta.
EU/1/09/530/011 30 tablets EU/1/09/530/012 90 tablets EU/1/09/530/013 120 tablets EU/1/09/530/014 270 tablets EU/1/09/530/015 360 tablets 
EU/1/09/530/011 30 tableta EU/1/09/530/012 90 tableta EU/1/09/530/013 120 tableta EU/1/09/530/014 270 tableta EU/1/09/530/015 360 tableta
In an interaction study in healthy volunteers, co-administration of 250 mg clarithromycin, a potent mechanism based inhibitor of CYP3A4, slightly increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. 
Istodobna primjena 250 mg klaritromicina, snažnog inhibitora CYP3A4, u ispitivanju interakcija provedenom na zdravim dobrovoljcima neznatno je povećala AUC repaglinida 1,4 puta i Cmax 1,7 puta te povećala srednju vrijednost AUC inzulina u serumu 1,5 puta i maksimalnu koncentraciju 1,6 puta.
Repaglinide Teva 2 mg tablets Microcrystalline cellulose (E460) Meglumine 
Repaglinid Teva 2 mg tablete celuloza, mikrokristalična (E460)
Repaglinide Teva 1 mg tablets Microcrystalline cellulose (E460) Meglumine 
Repaglinid Teva 1 mg tablete celuloza, mikrokristalična (E460)
EU/1/09/530/006 30 tablets EU/1/09/530/007 90 tablets EU/1/09/530/008 120 tablets EU/1/09/530/009 270 tablets EU/1/09/530/010 360 tablets 
EU/1/09/530/006 30 tableta EU/1/09/530/007 90 tableta EU/1/09/530/008 120 tableta EU/1/09/530/009 270 tableta EU/1/09/530/010 360 tableta
• Visual disturbances 
• zatvor • smetnje vida
Hypoglycaemia Repaglinide, like other insulin secretagogues, is capable of producing hypoglycaemia. 
Repaglinid, kao i drugi lijekovi koji potiču izlučivanje inzulina, može izazvati hipoglikemiju.
In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4 days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a 1.6-fold (90% CI [1.42-1.84]) increase in Cmax, and a small, significant decrease in blood glucose values. 
4 dana), umjerenog inhibitora CYP2C8 i CYP3A4 i repaglinida (pojedinačna doza od 0,5 mg) rezultirala je povećanjem sistemske izloženosti repaglinidu (AUC) za 2,3 puta (90% CI [2,03-2,63]) u odnosu na kontrolnu skupinu, povećanjem Cmax za 1,6 puta (90% CI [1,42-1,84]) i malim, ali značajnim sniženjem razine glukoze u krvi.
Common (may affect up to 1 in 10 patients) 
Često (mogu se javiti u do 1 na 10 bolesnika)
Repaglinide Teva 0.5 mg tablets Microcrystalline cellulose (E460) Meglumine 
Repaglinid Teva 0,5 mg tablete celuloza, mikrokristalična (E460)
In a study conducted in healthy volunteers, the concomitant administration of repaglinide (a single dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and Cmax about 2.5-fold and 1.8-fold respectively. 
U ispitivanju provedenom na zdravim dobrovoljcima, istodobna primjena repaglinida (pojedinačna doza od 0,25 mg) i ciklosporina (ponovljena doza od 100 mg) povećala je AUC repaglinida otprilike
EU/1/09/530/001 30 tablets EU/1/09/530/002 90 tablets EU/1/09/530/003 120 tablets EU/1/09/530/004 270 tablets EU/1/09/530/005 360 tablets 
EU/1/09/530/001 30 tableta EU/1/09/530/002 90 tableta EU/1/09/530/003 120 tableta EU/1/09/530/004 270 tableta EU/1/09/530/005 360 tableta
The use of repaglinide might be associated with an increased incidence of acute coronary syndrome (e.g. myocardial infarction), see sections 4.8 and 5.1. 
(primjerice, infarkt miokarda), vidjeti dijelove 4.8 i 5.1.
• ACE-inhibitors (used to treat heart conditions). 
• ACE inhibitore (koriste se za liječenje bolesti srca)
Warnings and precautions Talk to your doctor before taking Repaglinide Teva: 
Obratite se svom liječniku prije nego uzmete Repaglinid Teva: • Ako imate problema s jetrom.
Repaglinide Teva should be taken with caution. 
Potreban je oprez pri uzimanju lijeka Repaglinid Teva.
Repaglinide Teva 1 mg tablets Each tablet contains 1 mg of repaglinide. 
Svaka tableta sadrži 1 mg repaglinida.
• have frequent hypos, 
• imate česte hipoglikemije
- The other ingredients are: microcrystalline cellulose (E460), meglumine, poloxamer 188, povidone K-30, calcium hydrogen phosphate anhydrous, colloidal silicon dioxide anhydrous, polacrilin potassium, maize starch, magnesium stearate, indigo carmine aluminium (E132) (0.5 mg tablet only), iron oxide yellow (E172) (1 mg tablet only), iron oxide red (E172) (2 mg tablet only) 
bezvodni kalcijev hidrogenfosfat, koloidni bezvodni silicijev dioksid, polakrilinkalij, kukuruzni škrob, magnezijev stearat, indigo carmine aluminium (E132) (samo u tabletama od 0,5 mg), žuti željezov oksid (E172) (samo u tabletama od 1 mg), crveni željezov oksid (E172) (samo u tabletama od 2 mg).
Repaglinide Teva 2 mg tablets Each tablet contains 2 mg of repaglinide. 
Svaka tableta sadrži 2 mg repaglinida.
NAME OF THE MEDICINAL PRODUCT Repaglinide Teva 0.5 mg tablets Repaglinide 
NAZIV LIJEKA Repaglinid Teva 0,5 mg tablete repaglinid
How to store Repaglinide Teva 
Moguće nuspojave Kako čuvati Repaglinid Teva
NAME OF THE MEDICINAL PRODUCT Repaglinide Teva 0.5 mg tablets Repaglinide Teva 1 mg tablets Repaglinide Teva 2 mg tablets 
NAZIV LIJEKA Repaglinid Teva 0,5 mg tablete Repaglinid Teva 1 mg tablete
NAME OF THE MEDICINAL PRODUCT Repaglinide Teva 2 mg tablets Repaglinide 
NAZIV LIJEKA Repaglinid Teva 2 mg tablete repaglinid
NAME OF THE MEDICINAL PRODUCT Repaglinide Teva 1 mg tablets Repaglinide 
NAZIV LIJEKA Repaglinid Teva 1 mg tablete repaglinid
INFORMATION IN BRAILLE Repaglinide Teva 0.5 mg tablets 
16. PODACI NA BRAILLEOVOM PISMU Repaglinid Teva 0,5 mg tablete
INFORMATION IN BRAILLE Repaglinide Teva 1 mg tablets 
16. PODACI NA BRAILLEOVOM PISMU Repaglinid Teva 1 mg tablete
Repaglinide Teva 0.5 mg tablet is a light blue to blue, capsule shaped tablet, debossed with "93" on one side and “210” on the other side of the tablet. 
Repaglinid Teva 0.5 mg tableta je svijetloplava do plava tableta oblika kapsule, s utisnutom oznakom „93“ na jednoj strani te „210“ na drugoj strani tablete.
INFORMATION IN BRAILLE Repaglinide Teva 2 mg tablets 
16. PODACI NA BRAILLEOVOM PISMU Repaglinid Teva 2 mg tablete
• Itraconazole, ketokonazole (antifungal medicines). 
• itrakonazol, ketokonazol (koriste se za liječenje gljivica) • gemfibrozil (koristi se za snižavanje povišenih masnoća u krvi)
How to store Repaglinide Teva Contents of the pack and other information 
Sadržaj pakiranja i druge informacije Što Repaglinid Teva sadrži
Repaglinide Teva 1 mg tablet is a yellow to light yellow, capsule shaped tablet, debossed with "93" on one side and “211” on the other side of the tablet. 
Repaglinid Teva 1 mg tableta je žuta do svijetložuta tableta oblika kapsule, s utisnutom oznakom „93“ na jednoj strani te „211“ na drugoj strani tablete.
Repaglinide Teva is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar. 
S liječenjem se obično započinje kada se samo dijetom, tjelovježbom i smanjenjem tjelesne težine ne može postići zadovoljavajuća regulacija (ili snižavanje) razine šećera u krvi.
Repaglinide Teva 2 mg tablet is a mottled peach, capsule shaped tablet, debossed with "93" on one side and “212” on the other side of the tablet. 
Repaglinid Teva 2 mg tableta je išarana tableta boje breskve, oblika kapsule, s utisnutom oznakom „93“ na jednoj strani te „212“ na drugoj strani tablete.
Pharmacotherapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX02 
5.1 Farmakodinamička svojstva Farmakoterapijska skupina: lijekovi za liječenje šećerne bolesti, drugi lijekovi za snižavanje razine glukoze u krvi, osim inzulina.
Repaglinide Teva 0.5 mg tablets Repaglinide Teva 1 mg tablets Repaglinide Teva 2 mg tablets Repaglinide 
Repaglinid Teva 0,5 mg tablete repaglinid
6.5 Nature and contents of container Alu/Alu blisters. 
6.5 Vrsta i sadržaj spremnika
Repaglinide Teva is not recommended. 
Uzimanje lijeka Repaglinid Teva se ne preporučuje jer nije ispitivan u tim dobnim skupinama.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 0.5 mg of repaglinide. 
Svaka tableta sadrži 0,5 mg repaglinida.
Abdominal pain, diarrhoea Common Vomiting, constipation Very rare Nausea 
Bol u abdomenu, proljev
Combination with insulin secretagogues 
Kombinacija s metforminom
Maintenance 
PROMET
Repaglinide Teva 2 mg tablets Mottled peach, capsule shaped tablet, debossed with "93" on one side and “212” on the other side. 
Išarana tableta boje breskve, oblika kapsule, s utisnutom oznakom „93“ na jednoj strani te „212“ na drugoj strani tablete.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturers responsible for batch release Teva Pharmaceutical Works Private Limited Company Pallagi ut 13 
Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet
Magnesium stearate 
NAVOĐENJE DJELATNE TVARI
*See next section below 
*Vidjeti sljedeći odjeljak ispod
Tell your doctor what happened. 
Obavijestite liječnika što se dogodilo.
Repeat step 5 three times. 
Ponovite 5. korak tri puta.
Blow your nose if you feel you need to. 
Ispuhnite nos ako osjećate da je potrebno.
Elderly (older than 65 years) 
Stariji bolesnici (u dobi iznad 65 godina)
The patient should be instructed how to do this correctly. 
Bolesnika se mora uputiti kako to učiniti pravilno.
It is very important to follow your doctor's instructions. 
Veoma je važno da se pridržavate liječnikovih uputa.
• Do not change the dose yourself. 
• Ne mijenjajte dozu sami.
• not knowing where you are (disorientated) 
• ne znate gdje se nalazite (dezorijentiranost)
• difficulty in speaking 
• teškoće s govorom
The relevance of these findings to humans is unknown. 
Važnost ovog nalaza za ljude nije poznata.
Abuse potential and tolerance 
Mogućnost zlouporabe i tolerancija
Patients should be carefully monitored until an effective dose is reached. 
Bolesnike se mora pažljivo nadzirati dok se ne postigne djelotvorna doza.
The main pharmacokinetic parameters are shown in the following table. 
Glavni farmakokinetički parametri prikazani su u sljedećoj tablici.
• you suffer a severe blow to the head 
• ako ste pretrpjeli snažan udarac u glavu
Sit down with your head upright. 
Sjednite držeći glavu uspravno.
Coma is also known to occur. 
Poznato je da može nastupiti i koma.
<1/1,000); very rare (<1/10,000); unknown (cannot be estimated from available data)). 
vrlo rijetko (< 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka)).
• changes in blood cells (detected by laboratory tests) 
• promjene krvnih stanica (ustanovljene laboratorijskim pretragama)
The safety and efficacy of PecFent in children and adolescents aged below 18 years have not yet been established. 
Sigurnost i djelotvornost lijeka PecFent u djece i adolescenata mlađih od 18 godina nisu još ustanovljene.
micrograms micrograms micrograms micrograms micrograms 
mikrograma mikrograma mikrograma mikrograma mikrograma
One hundred of these patients continued treatment for up to 26 months in an extension phase. 
Od tih bolesnika, njih stotinu nastavilo je liječenje do 26 mjeseci u fazi produžetka ispitivanja.
If this happens, do not drive or use any tools or machines. 
Ako se to dogodi, ne vozite ili ne rukujte alatima ili strojevima.
Call an ambulance or ask someone else to call one straight away if you: 
Odmah pozovite hitnu pomoć ili zamolite nekog drugog da to učini ako:
Dose increase should be undertaken with caution. 
Povećanje doze se mora provoditi s oprezom.
Patients should not use more than 4 doses per day. 
Bolesnici ne smiju primijeniti više od 4 doze na dan.
Your doctor may need to check the dose. 
Liječnik će možda trebati provjeriti dozu.
PecFent is not approved for use in children under 18 years of age. 
PecFent nije odobren za primjenu u djece mlađe od 18 godina.
Bottles contain: 
Bočice sadrže:
This will tilt the bottle slightly (Figure 5). 
Time ćete bočicu neznatno nagnuti (slika 5).
Contents of the pack and other information What PecFent contains 
Sadržaj pakiranja i druge informacije Što PecFent sadrži
• The counter will stay on the number “8”. 
• Brojač će ostati na broju „8”.
Of the patients entering the titration phase, only 7 (6.1 %) were unable to be titrated to an effective dose due to lack of efficacy and 6 (5.3 %) withdrew due to adverse events. 
Od bolesnika koji su ušli u fazu titracije samo njih 7 (6,1%) nije bilo moguće titrirati na djelotvornu dozu zbog nedostatka djelotvornosti, a 6 bolesnika (5,3%) povučeno je zbog štetnih događaja.
L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A Strada Statale 67 Tosco Romagnola, Fraz. 
Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A Strada Statale 67 Tosco Romagnola, Fraz.
If this occurs, patients should be advised to discontinue their decongestant. 
Ako se to dogodi, bolesnike se mora savjetovati da prekinu primjenu dekongestiva.
The risk of side effects increases if you are taking medicines such as certain antidepressants or antipsychotics. 
Rizik od nuspojava povećava se ako uzimate lijekove kao što su neki antidepresivi ili antipsihotici.
Your doctor will tell you how many sprays (1 or 2) you should use to treat your breakthrough pain episode. 
Liječnik će Vam reći koliko potisaka morate primijeniti (1 ili 2) za liječenje epizode probijajuće boli.
Date of first authorisation: 31 August 2010 Date of latest renewal: 17 July 2015 
Datum posljednje obnove odobrenja: 17 srpanj 2015
Therefore it is not possible to definitively separate the effects of PecFent alone. 
Stoga nije moguće jasno odvojiti učinke samog PecFenta.
This will go up to the number 2 when the spray is used again. 
Broj će se povećati do broja 2 kada ponovno upotrijebite sprej.
Granatieri - 50018 Scandicci (FI) Italy 
Granatieri - 50018 Scandicci (FI) Italija
• Do not use PecFent if you are pregnant or might get pregnant, unless your doctor has told you to. 
• Ne primjenjujte PecFent ako ste trudni ili biste mogli zatrudnjeti, osim ako Vam je to rekao liječnik.
The 2 spray bottle cannot be re-primed and once both doses are used, or if longer than 5 days since priming, the bottle and contents should be discarded as described in section 6.6. 
Bočica sa 2 potiska ne može se ponovno aktivirati, a jednom kada su iskorištene obje doze, ili kada je proteklo više od 5 dana od aktiviranja, bočicu i njezin sadržaj treba baciti onako kako je opisano u dijelu 6.6.
For 8 spray bottle: 1, 4 or 12 bottles. 
Za bočicu sa 8 potisaka: 1, 4 ili 12 bočica.
Keep out of the sight and reach of children (Figure 6) 
Čuvati izvan pogleda i dohvata djece (slika 6).
Serotonin Syndrome 
Serotoninski sindrom
• change in taste 
• promjena okusa
• seeing or hearing things that are not really there (hallucinations/delirium), feeling confused 
• vidite ili čujete ono što ne postoji (halucinacije/delirij), osjećaj smetenosti
• The counter will stay on the number “2”. 
• Brojač će ostati na broju ”2”.
• you have problems with your heart especially slow heart rate 
• ako imate tegobe sa srcem, posebno sa sporim otkucajima srca
Of the 355 patients treated in the open-label treatment phase, 90 % required no increase in dose. 
Od 355 bolesnika liječenih u fazi liječenja otvorenog tipa, za 90% bolesnika nije bilo potrebno povećavati dozu.
PecFent should not be disposed of via wastewater or household waste. 
PecFent se ne smije bacati u otpadne vode ili kućni otpad.
It should be noted that although statistically significant increases in Cmax levels were seen following a second dose of PecFent given either one or two hours after the initial dose, this increase is not considered to be large enough to suggest that clinically concerning accumulation or over-exposure would occur, providing a wide safety margin for the recommended dose interval of four hours. 
Mora se napomenuti da iako su opažena statistički značajna povećanja razina Cmax nakon druge doze PecFenta primijenjenog jedan ili dva sata poslije početne doze, to se povećanje ne smatra dovoljno velikim da bi ukazivalo da će se dogoditi klinički zabrinjavajuće nakupljanje ili prevelika izloženost, što daje široku sigurnosnu granicu za preporučeni dozni interval od četiri sata.
Less than 7 % of an administered dose of fentanyl is excreted unchanged in the urine and only about 1 % is excreted unchanged in the faeces. 
Manje od 7% primijenjene doze fentanila izlučuje se nepromijenjeno u mokraći, a samo oko 1% izlučuje se nepromijenjeno u stolici.
The plasma protein binding of fentanyl is 80 - 85 %. 
Na proteine plazme veže se 80 - 85% fentanila.
• you have low blood pressure or a low amount of fluid in your circulation 
• ako imate nizak krvni tlak ili malu količinu tekućine u optoku
To prime the bottle, please follow the instructions below: 
Da biste aktivirali bočicu, slijedite ove upute:
Never try to fix the nasal spray yourself or take it apart. 
Nikada ne pokušavajte sprej za nos popraviti sami i nikada ga ne pokušavajte rastaviti.
It can increase the risk of getting serious side effects. 
Time biste mogli povećati rizik od pojave ozbiljnih nuspojava.
If you have not been using these medicines you must not use PecFent, because it may increase the risk that breathing could become dangerously slow and/or shallow, or even stop. 
Ako niste uzimali ove lijekove ne smijete uzeti PecFent jer može povećati rizik od opasnog usporavanja disanja i/ili plitkog disanja ili čak potpunog prestanka disanja.